The Chemours Company (NYSE:CC) Shares Sold by Intech Investment Management LLC

Intech Investment Management LLC trimmed its holdings in shares of The Chemours Company (NYSE:CC) by 46.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 18,375 shares of the specialty chemicals company’s stock after selling 15,812 shares during the quarter. Intech Investment Management LLC’s holdings in Chemours were worth $373,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. KBC Group NV increased its position in shares of Chemours by 19.5% during the 3rd quarter. KBC Group NV now owns 4,468 shares of the specialty chemicals company’s stock worth $91,000 after purchasing an additional 728 shares during the last quarter. Blue Trust Inc. boosted its holdings in Chemours by 166.9% during the 3rd quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company’s stock valued at $26,000 after acquiring an additional 731 shares during the period. Arizona State Retirement System boosted its holdings in Chemours by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 41,657 shares of the specialty chemicals company’s stock valued at $940,000 after acquiring an additional 863 shares during the period. State of Alaska Department of Revenue boosted its holdings in Chemours by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 17,205 shares of the specialty chemicals company’s stock valued at $349,000 after acquiring an additional 1,175 shares during the period. Finally, Signaturefd LLC boosted its holdings in Chemours by 163.7% during the 3rd quarter. Signaturefd LLC now owns 1,959 shares of the specialty chemicals company’s stock valued at $40,000 after acquiring an additional 1,216 shares during the period. 76.26% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

CC has been the subject of a number of research analyst reports. BMO Capital Markets raised their target price on Chemours from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Monday, October 7th. Royal Bank of Canada lowered their target price on Chemours from $28.00 to $25.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. The Goldman Sachs Group decreased their price objective on Chemours from $29.00 to $23.00 and set a “neutral” rating for the company in a research note on Tuesday, September 3rd. JPMorgan Chase & Co. decreased their price objective on Chemours from $25.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, August 6th. Finally, UBS Group decreased their price objective on Chemours from $30.00 to $28.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Five analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, Chemours has an average rating of “Hold” and a consensus target price of $24.88.

Insiders Place Their Bets

In other Chemours news, SVP Alvenia Scarborough sold 7,500 shares of Chemours stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $20.64, for a total transaction of $154,800.00. Following the transaction, the senior vice president now owns 16,645 shares of the company’s stock, valued at $343,552.80. The trade was a 31.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.47% of the stock is currently owned by corporate insiders.

Chemours Price Performance

Shares of NYSE CC opened at $21.63 on Wednesday. The company has a debt-to-equity ratio of 6.05, a quick ratio of 0.92 and a current ratio of 1.73. The Chemours Company has a fifty-two week low of $15.10 and a fifty-two week high of $32.70. The firm has a market capitalization of $3.23 billion, a PE ratio of 43.26 and a beta of 1.80. The stock’s 50-day simple moving average is $19.77 and its 200-day simple moving average is $21.19.

Chemours (NYSE:CC) last issued its earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.08. Chemours had a return on equity of 29.48% and a net margin of 1.34%. The business had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.44 billion. During the same quarter last year, the company earned $0.64 EPS. The business’s quarterly revenue was up .9% on a year-over-year basis. As a group, equities research analysts forecast that The Chemours Company will post 1.35 EPS for the current fiscal year.

Chemours Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Friday, November 15th will be given a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 4.62%. The ex-dividend date of this dividend is Friday, November 15th. Chemours’s dividend payout ratio (DPR) is presently 200.00%.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.